Format

Send to

Choose Destination
Int J Mol Sci. 2017 Jan 29;18(2). pii: E264. doi: 10.3390/ijms18020264.

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.

Author information

1
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France. J-vendrell@chu-montpellier.fr.
2
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France. f-tran_mau_them@chu-montpellier.fr.
3
IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France. benoit.beganton@inserm.fr.
4
INSERM, U1194, 34298 Montpellier, France. benoit.beganton@inserm.fr.
5
ICM, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France. benoit.beganton@inserm.fr.
6
Université de Montpellier, 34000 Montpellier, France. benoit.beganton@inserm.fr.
7
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Microbiology, 34295 Montpellier, France. S-godreuil@chu-montpellier.fr.
8
IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France. peter.coopman@inserm.fr.
9
INSERM, U1194, 34298 Montpellier, France. peter.coopman@inserm.fr.
10
ICM, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France. peter.coopman@inserm.fr.
11
Université de Montpellier, 34000 Montpellier, France. peter.coopman@inserm.fr.
12
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France. j-solassol@chu-montpellier.fr.
13
IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France. j-solassol@chu-montpellier.fr.
14
INSERM, U1194, 34298 Montpellier, France. j-solassol@chu-montpellier.fr.
15
Université de Montpellier, 34000 Montpellier, France. j-solassol@chu-montpellier.fr.

Abstract

Circulating tumoral DNA (ctDNA), commonly named "liquid biopsy", has emerged as a new promising noninvasive tool to detect biomarker in several cancers including lung cancer. Applications involving molecular analysis of ctDNA in lung cancer have increased and encompass diagnosis, response to treatment, acquired resistance and prognosis prediction, while bypassing the problem of tumor heterogeneity. ctDNA may then help perform dynamic genetic surveillance in the era of precision medicine through indirect tumoral genomic information determination. The aims of this review were to examine the recent technical developments that allowed the detection of genetic alterations of ctDNA in lung cancer. Furthermore, we explored clinical applications in patients with lung cancer including treatment efficiency monitoring, acquired therapy resistance mechanisms and prognosis value.

KEYWORDS:

circulating DNA; lung cancer; molecular diagnosis; routine practice; targeted therapies

PMID:
28146051
PMCID:
PMC5343800
DOI:
10.3390/ijms18020264
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center